Literature DB >> 4744012

Serum-mediated leukemia cell destruction in AKR mice.

R L Kassel, L J Old, E A Carswell, N C Fiore, W D Hardy.   

Abstract

AKR mice with spontaneous leukemia were infused with normal serum from a variety of species. Leukemia cell destruction was produced by serum from strains of mice possessing the full spectrum of complement components, but not by serum from strains with a genetically determined deficiency of C5. Serum from guinea pigs, horses, and humans also causes destruction of leukemia cells. The antileukemic factor in normal serum was heat labile (56 degrees C for 35 min) and could be inactivated by cobra venom factor (CVF). Tests of individual complement factors from guinea pig serum and from human serum suggest that C5 is the antileukemic complement component in normal serum. Evidence was obtained that complement also plays a role in the antileukemic effect of interferon and endotoxin.

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4744012      PMCID： PMC2180560          DOI： 10.1084/jem.138.4.925

Source DB:  PubMed          Journal:  J Exp Med        ISSN： 0022-1007            Impact factor:   14.307


  25 in total

1.  The G (Gross) leukemia antigen.

Authors:  L J Old; E A Boyse; E Stockert
Journal:  Cancer Res       Date:  1965-07       Impact factor: 12.701

2.  Isolation of the anticomplementary protein from cobra venom and its mode of action on C3.

Authors:  H J Müller-Eberhard; K E Fjellström
Journal:  J Immunol       Date:  1971-12       Impact factor: 5.422

3.  Carcinolytic effects of interferon.

Authors:  R L Kassel
Journal:  Clin Obstet Gynecol       Date:  1970-12       Impact factor: 2.190

4.  Serum complement level in patients with leukemia.

Authors:  S Yoshikawa; K Yamada; T O Yoshida
Journal:  Int J Cancer       Date:  1969-11-15       Impact factor: 7.396

5.  Prevention of the localized and generalized Shwartzman reactions by an anticomplementary agent, cobra venom factor.

Authors:  J S Fong; R A Good
Journal:  J Exp Med       Date:  1971-09-01       Impact factor: 14.307

6.  A study of passive immunization against a transplanted G+ leukemia with specific antiserum.

Authors:  L J Old; E Stockert; E A Boyse; G Geering
Journal:  Proc Soc Exp Biol Med       Date:  1967-01

7.  Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum.

Authors:  R A Nelson; J Jensen; I Gigli; N Tamura
Journal:  Immunochemistry       Date:  1966-03

8.  Wild-type Gross leukemia virus and the pathogenesis of the glomerulonephritis of New Zealand mice.

Authors:  R C Mellors; T Shirai; T Aoki; R J Huebner; K Krawczynski
Journal:  J Exp Med       Date:  1971-01-01       Impact factor: 14.307

9.  Antigens of leukemias induced by naturally occurring murine leukemia virus: their relation to the antigens of gross virus and other murine leukemia viruses.

Authors:  G Geering; L J Old; E A Boyse
Journal:  J Exp Med       Date:  1966-10-01       Impact factor: 14.307

10.  DISTRIBUTION, INHERITANCE, AND PROPERTIES OF AN ANTIGEN, MUB1, AND ITS RELATION TO HEMOLYTIC COMPLEMENT.

Authors:  B CINADER; S DUBISKI; A C WARDLAW
Journal:  J Exp Med       Date:  1964-11-01       Impact factor: 14.307
View more
  12 in total

Review 1.  Interferons: anti-neoplastic drugs?

Authors:  H Strander
Journal:  Blut       Date:  1977-09-18

2.  In vivo effects of rabbit anti-mouse brain serum on theta bearing lymphocytes of AKR mice.

Authors:  J A Filppi; M S Rheins; R L Pierre
Journal:  Immunology       Date:  1975-04       Impact factor: 7.397

Review 3.  Immunopathology induced by the feline leukemia virus.

Authors:  W D Hardy
Journal:  Springer Semin Immunopathol       Date:  1982

4.  Chimeric univalent antibodies for treating lymphoid malignancies.

Authors:  G T Stevenson; V M Cole; J Summerton; H F Watts
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

5.  Optimal strategies in immunology III. The IgM-IgG switch.

Authors:  A S Perelson; B Goldstein; S Rocklin
Journal:  J Math Biol       Date:  1980-11       Impact factor: 2.259

6.  Phagocytosis of monocytes in cancer patients.

Authors:  B M Kuntz; R M Kuntz; E D Albert
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1978-01-26

7.  Changes in expression of murine leukemia virus antigens and production of xenotropic virus in the late preleukemic period in AKR mice.

Authors:  K Kawashima; H Ikeda; J W Hartley; E Stockert; W P Rowe; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1976-12       Impact factor: 11.205

Review 8.  Host resistance to metastasis from mouse mammary carcinomas.

Authors:  J Vaage; D Glaves-Rapp
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

9.  Binding of components of the properdin system to cultured human lymphoblastoid cells and B lymphocytes.

Authors:  A N Theofilopoulos; L H Perrin
Journal:  J Exp Med       Date:  1976-02-01       Impact factor: 14.307

10.  G(AKSL2): a new cell surface antigen of the mouse related to the dualtropic mink cell focus-inducing class of murine leukemia virus detected by naturally occurring antibody.

Authors:  E Stockert; A B DeLeo; P V O'Donnell; Y Obata; L J Old
Journal:  J Exp Med       Date:  1979-01-01       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.